Skip to main content

Dolasetron Side Effects

Medically reviewed by Last updated on Nov 11, 2023.

Applies to dolasetron: oral tablet. Other dosage forms:

Serious side effects of Dolasetron

Along with its needed effects, dolasetron may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dolasetron:

More common

Less common


Other side effects of Dolasetron

Some side effects of dolasetron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common


For Healthcare Professionals

Applies to dolasetron: intravenous solution, oral tablet.


The most common side effects include headache, constipation, sleep disorders, and dizziness.[Ref]

Nervous system

Loss of consciousness may occur immediately/closely after an IV bolus in patients receiving treatment for prophylaxis of chemotherapy induced nausea and vomiting.

Headache and dizziness occurred more frequently at higher doses.[Ref]

Very common (10% or more): Headache (up to 41.1%), dizziness (up to 12.5%), drowsiness (up to 10.5%)

Rare (0.01% to 0.1%): Seizure, syncope

Frequency not reported: Taste perversion, vertigo, paresthesia, tremor, ataxia

Postmarketing reports: Loss of consciousness[Ref]


Very common (10% or more): Constipation (up to 28.6%), dyspepsia (up to 12.8%), diarrhea (up to 11.1%), abdominal pain (up to 10.2%)

Rare (0.01% to 0.1%): Intestinal obstruction, pancreatitis[Ref]


Very common (10% or more): Sleep disorder (up to 12.8%)

Frequency not reported: Agitation, depersonalization, confusion, anxiety, abnormal dreaming[Ref]


Very common (10% or more): Fatigue (up to 12.2%)

Common (1% to 10%): Pain, fever, chills/shivering

Frequency not reported: Tinnitus

Postmarketing reports: Facial edema[Ref]


Severe hypotension and bradycardia occurred immediately/closely after an IV bolus in patients receiving treatment for prophylaxis of chemotherapy induced nausea and vomiting.

Wide complex tachycardia, ventricular tachycardia, and ventricular fibrillation/cardiac arrest were rarely reported after IV administration.[Ref]

Common (1% to 10%): Bradycardia (mostly sinus), hypotension, tachycardia (mostly sinus)

Uncommon (0.1% to 1%): Chest pain, orthostatic hypotension, hypertension

Rare (0.01% to 0.1%): Myocardial ischemia, edema

Frequency not reported: T wave change, ST-T wave change, sinus arrhythmia, extrasystole (atrial/ventricular premature contractions), poor R wave progression, left and right bundle branch block, nodal arrhythmias, U wave change, atrial flutter/fibrillation, peripheral edema, Mobitz I AV block, palpitations, peripheral ischemia, thrombophlebitis/phlebitis

Postmarketing reports: Severe hypotension, wide complex tachycardia, ventricular tachycardia, ventricular fibrillation/cardiac arrest, shock[Ref]


Common (1% to 10%): Increased serum transaminases (AST, ALT)

Rare (0.01% to 0.1%): Jaundice

Frequency not reported: Hyperbilirubinemia, increased GGT[Ref]

Increased serum transaminases occurred more frequently in patients treated during IV chemotherapy/radiotherapy than those treated during postoperative therapy/IV surgery; however, the increases did not appear to be related to dose/duration of therapy, and were not associated with symptomatic hepatic disease.[Ref]


Respiratory side effects have rarely included dyspnea and bronchospasm.[Ref]


Frequency not reported: Prothrombin time prolonged, partial thromboplastin time (PTT) increased, anemia, purpura/hematoma, thrombocytopenia[Ref]


Frequency not reported: Hematuria, dysuria, urinary retention, polyuria[Ref]


Frequency not reported: Increased sweating, flushing, rash

Postmarketing reports: Urticaria[Ref]


Frequency not reported: Myalgia, arthralgia, twitching[Ref]


Frequency not reported: Anorexia, increased alkaline phosphatase[Ref]


Frequency not reported: Abnormal vision, photophobia[Ref]


Frequency not reported: Acute renal failure[Ref]


Postmarketing reports: Anaphylactic/anaphylactoid reactions, angioedema[Ref]


Postmarketing reports: Local pain/burning (IV formulation)[Ref]


1. Product Information. Anzemet (dolasetron). Hoechst Marion Roussel. 2001;PROD.

2. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.